Table 1. Association between individual study characteristics and CD209 gene polymorphisms.
| Study | Origin | Ethnicity | Male patients (%) | Mean age(years) | Sample types | Sample size | Polymorphisms investigated | Clinical diagnoses performed | Control source | Genotypingmethod | Score | ||
| Cases | Controls | Cases | Controls | ||||||||||
| Kobayashi et al. [12] | Indonesian | Asian | 53.7 | 41.6±15.4 | 39.3±12.7 | PTB | 532 | 561 | -336A/G, -871A/G | Smear, radiologic,clinical symptoms | Healthy individuals | Sequencing | 8 |
| Ogarkov et al. [17] | Russian | Caucasian | 76.3 | 42.3±12.1 | 41.9±9.2 | PTB | 101 | 177 | -336A/G | NR | Healthy individuals | Taq Man LNA technology | 7 |
| EPTB | 90 | ||||||||||||
| Zheng et al. [19] | Chinese | Asian | 65.4 | 44.6±17.7 | NR | PTB | 237 | 244 | -336A/G, -871A/G | Culture, radiologic | Healthy individuals | Sequencing | 7 |
| Sadki et al. [15] | Moroccan | Mixed | 81.1 | 33.7±13.2 | NR | PTB | 122 | 151 | -336A/G | Smear, culture,histology, radiologic,clinical symptoms | Healthy unrelateddonors | Taq Man SNP genotyping assays | 8 |
| Selvaraj et al. [13] | Indian | Caucasian | 61.2 | 34.0±8.2 | 30.6±8.3 | PTB | 183 | 157 | -336A/G | Smear, culture,radiologic, clinicalsymptoms | Healthy individuals | PCR-RFLP | 7 |
| EPTB | 31 | ||||||||||||
| Zhuang et al. [20] | Chinese | Asian | 65.9 | 43(16–77) | 30(15–78) | PTB | 167 | 167 | -336A/G | Smear, culture,histology, radiologic,clinical symptoms | Healthy unrelateddonors with nohistory ofautoimmunedisease | SSP-PCR | 7 |
| Vannberg et al. (a) [14] | Gambian | African | NR | NR | NR | PTB | 676 | 327 | -336A/G | Smear, culture,histology | Healthy unrelateddonors | MALDI-TOF | 8 |
| Vannberg et al. (b) [14] | Guinean | African | NR | NR | NR | PTB | 151 | 180 | -336A/G | Smear, culture,histology | Healthy unrelated donors | MALDI-TOF | 8 |
| Vannberg et al. (c) [14] | Guinea-Bissau | African | NR | NR | NR | PTB | 162 | 141 | -336A/G | Smear, culture,histologyconfirmed TB | Healthy unrelateddonors | MALDI-TOF | 8 |
| Vannberg et al. (d) [14] | Malawian | African | NR | NR | NR | PTB | 244 | 295 | -336A/G | Smear, culture,histologyconfirmed TB | Healthy unrelated donors | MALDI-TOF | 8 |
| Ben-Ali et al. [18] | Tunisian | Mixed | NR | NR(18–65) | NR(25–60) | NR | 138 | 140 | -336A/G, -871A/G | Smear, culture,radiologic, clinicalsymptoms confirmedTB | Healthy unrelateddonors | Sequencing | 8 |
| Olesen et al. [16] | Guinea-Bissau | African | 60.4 | 37.3 | 38.1 | PTB | 315 | 340 | -336A/G | Smear, culture,histology, radiologic,clinical symptomsconfirmed TB | Healthy unrelateddonors | Taq Man SNP genotyping assays | 9 |
| Barreiro et al. [6] | SouthAfrican | African | 51.8 | 36.7±10.9 | 34.6±12.5 | PTB | 351 | 360 | -336A/G, -871A/G | Smear, cultureconfirmed TB | Healthy unrelateddonors | Taq Man or fluorescence polarization | 8 |
| Gómez et al. [11] | Colombian | Mixed | 14.5 | 40.0±15.0 | NR | NR | 110 | 299 | -336A/G | Smear, cultureconfirmed TB | Healthy unrelateddonors with nohistory ofautoimmunedisease | Sequencing | 8 |
Abbreviations and definitions: PTB, pulmonary tuberculosis; EPTB, extra-pulmonary tuberculosis; NR, not report; PCR-RFLP, Polymerase Chain Reaction-Restriction Fragment Length Polymorphism; SSP-PCR, sequence specific primer-Polymerase Chain Reaction; MALDI-TOF, Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry.